Which countries run stem-cell trials for Muscular Dystrophy?
Sampled registrations place sites in 17 countries. United States is the largest single contributor at roughly 35% of country mentions. Snapshot 2026-08-29.
Country distribution
| Country | Studies with a site there |
|---|---|
| United States | 9 |
| India | 6 |
| Turkey (Türkiye) | 2 |
| South Korea | 2 |
| Australia | 2 |
| Jordan | 1 |
| Israel | 1 |
| Iran | 1 |
| Netherlands | 1 |
| Belgium | 1 |
A study with sites in several countries is counted once per country, taken from the location block of each registry record.
What the map means for Muscular Dystrophy
Registered work follows neuromuscular centres with genetic diagnostics and standardised functional assessment. Marketing to families internationally rarely distinguishes between gene-targeted trials and generic cell infusions.
Where recruitment is actually open
| Country | Open studies with a site there |
|---|---|
| United States | 3 |
| Israel | 1 |
| Australia | 1 |
| Belgium | 1 |
| Canada | 1 |
| Poland | 1 |
| Serbia | 1 |
| Spain | 1 |
What travelling for a trial actually involves
Cross-border participation fails on logistics more often than on eligibility: follow-up schedules, local insurance, visa duration and who pays for complications. A site that cannot answer those in writing is not going to enrol you.
Multi-country studies, named
Registered studies with sites in more than one country — the clearest evidence of collaboration rather than a single-centre series.
- NCT07287189 — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients (Australia, Belgium, Canada, Poland, Serbia, Spain)
- NCT02987855 — Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia (Honduras, United States)
Why trial geography is not a shortlist
Registration geography is a proxy for research infrastructure, not for outcomes. The relevant question about any destination is what oversight applies to the specific product you would receive there, which is a different enquiry entirely.
Before treating geography as a shortlist, read the legality overview by country and what "best country" actually means here.
When these studies started
Registrations by start year since 2020: 2020 (1), 2022 (1), 2024 (4), 2025 (3). Activity for this condition spans 2008 to 2025, which shows whether interest is growing, flat or past its peak.
Frequently asked
Which countries run stem-cell trials for Muscular Dystrophy?
Sites are registered in 17 countries; the largest is United States (~35% of country mentions, 2026-08-29).
Does a country with many trials mean better treatment there?
Volume tracks funding and law, not outcomes. The relevant question is what oversight covers the specific clinic and product you are considering.
Are trial sites and commercial clinics the same thing?
Rarely. Academic trial sites and the private clinics advertising to medical tourists are typically separate organisations with different oversight.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.